New! Search for patents from more than 100 countries including Australia, Brazil, Sweden and more

WO2004006906A3 - Methods for the treatment of neoplasms - Google Patents

Methods for the treatment of neoplasms Download PDF

Info

Publication number
WO2004006906A3
WO2004006906A3 PCT/US2003/022026 US0322026W WO2004006906A3 WO 2004006906 A3 WO2004006906 A3 WO 2004006906A3 US 0322026 W US0322026 W US 0322026W WO 2004006906 A3 WO2004006906 A3 WO 2004006906A3
Authority
WO
WIPO (PCT)
Prior art keywords
neoplasms
treatment
methods
neoplasm
patient
Prior art date
Application number
PCT/US2003/022026
Other languages
French (fr)
Other versions
WO2004006906A2 (en
Inventor
Margaret S Lee
Curtis Keith
Benjamin A Auspitz
Grant R Zimmermann
M James Nichols
Michael A Foley
Original Assignee
Combinatorx Inc
Margaret S Lee
Curtis Keith
Benjamin A Auspitz
Grant R Zimmermann
M James Nichols
Michael A Foley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US39613502P priority Critical
Priority to US39613602P priority
Priority to US60/396,136 priority
Priority to US60/396,135 priority
Priority to US40096302P priority
Priority to US40091302P priority
Priority to US60/400,913 priority
Priority to US60/400,963 priority
Priority to US60/460,203 priority
Priority to US46020303P priority
Priority to US46034803P priority
Priority to US60/460,348 priority
Application filed by Combinatorx Inc, Margaret S Lee, Curtis Keith, Benjamin A Auspitz, Grant R Zimmermann, M James Nichols, Michael A Foley filed Critical Combinatorx Inc
Publication of WO2004006906A2 publication Critical patent/WO2004006906A2/en
Publication of WO2004006906A3 publication Critical patent/WO2004006906A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/609Amides, e.g. salicylamide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The invention features a method for treating a patient having a cancer or other neoplasm by administering to the patient a niclosamide, or a structural or functional analog thereof, and, optionally, one or more antiproliferative agents in an amount effective to inhibit the growth of the neoplasm.
PCT/US2003/022026 2002-07-15 2003-07-15 Methods for the treatment of neoplasms WO2004006906A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
US39613502P true 2002-07-15 2002-07-15
US39613602P true 2002-07-15 2002-07-15
US60/396,136 2002-07-15
US60/396,135 2002-07-15
US40091302P true 2002-08-02 2002-08-02
US40096302P true 2002-08-02 2002-08-02
US60/400,913 2002-08-02
US60/400,963 2002-08-02
US46020303P true 2003-04-03 2003-04-03
US46034803P true 2003-04-03 2003-04-03
US60/460,348 2003-04-03
US60/460,203 2003-04-03

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2003249244A AU2003249244A1 (en) 2002-07-15 2003-07-15 Methods for the treatment of neoplasms

Publications (2)

Publication Number Publication Date
WO2004006906A2 WO2004006906A2 (en) 2004-01-22
WO2004006906A3 true WO2004006906A3 (en) 2004-03-04

Family

ID=31982762

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/022026 WO2004006906A2 (en) 2002-07-15 2003-07-15 Methods for the treatment of neoplasms

Country Status (2)

Country Link
AU (1) AU2003249244A1 (en)
WO (1) WO2004006906A2 (en)

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
US8569323B2 (en) 2009-07-15 2013-10-29 Intellikine, Llc Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof
US8604032B2 (en) 2010-05-21 2013-12-10 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
US8637542B2 (en) 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
US8642604B2 (en) 2006-04-04 2014-02-04 The Regents Of The University Of California Substituted pyrazolo[3,2-d]pyrimidines as anti-cancer agents
US8697709B2 (en) 2008-10-16 2014-04-15 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
US8703777B2 (en) 2008-01-04 2014-04-22 Intellikine Llc Certain chemical entities, compositions and methods
US8785470B2 (en) 2011-08-29 2014-07-22 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8785454B2 (en) 2009-05-07 2014-07-22 Intellikine Llc Heterocyclic compounds and uses thereof
US8809349B2 (en) 2011-01-10 2014-08-19 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US8901133B2 (en) 2010-11-10 2014-12-02 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8969347B2 (en) 2008-06-03 2015-03-03 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US8969363B2 (en) 2011-07-19 2015-03-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
US9056877B2 (en) 2011-07-19 2015-06-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9096611B2 (en) 2008-07-08 2015-08-04 Intellikine Llc Kinase inhibitors and methods of use
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
US9321772B2 (en) 2011-09-02 2016-04-26 The Regents Of The University Of California Substituted pyrazolo[3,4-D]pyrimidines and uses thereof
US9359379B2 (en) 2012-10-02 2016-06-07 Intermune, Inc. Anti-fibrotic pyridinones
US9359365B2 (en) 2013-10-04 2016-06-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9359349B2 (en) 2007-10-04 2016-06-07 Intellikine Llc Substituted quinazolines as kinase inhibitors
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9512125B2 (en) 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
US9527816B2 (en) 2005-05-10 2016-12-27 Intermune, Inc. Method of modulating stress-activated protein kinase system

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070208087A1 (en) 2001-11-02 2007-09-06 Sanders Virginia J Compounds, compositions and methods for the treatment of inflammatory diseases
EP2527315B1 (en) 2002-05-31 2014-03-19 Proteotech Inc. Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as Alzheimer's disease, type 2 diabetes and Parkinson's disease
CN100406006C (en) * 2003-07-16 2008-07-30 株式会社医药分子设计研究所 Chromatosis remedies
US20050250709A1 (en) * 2003-12-19 2005-11-10 Bionaut Pharmaceuticals Anti-neoplastic agents, combination therapies and related methods
US7531560B2 (en) 2004-11-10 2009-05-12 Boehringer Ingelheim Pharmaceuticals, Inc. Anti-cytokine heterocyclic compounds
US7671058B2 (en) 2006-06-21 2010-03-02 Institute Of Medicinal Molecular Design, Inc. N-(3,4-disubstituted phenyl) salicylamide derivatives
WO2008021088A2 (en) 2006-08-08 2008-02-21 The Regents Of The University Of Californina Salicylanilides enhance oral delivery of therapeutic peptides
WO2008031534A1 (en) 2006-09-11 2008-03-20 Syngenta Participations Ag Insecticidal compounds
US9078888B2 (en) 2007-01-22 2015-07-14 Gtx, Inc. Nuclear receptor binding agents
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
GB0711957D0 (en) * 2007-06-21 2007-08-01 Syntopix Ltd Formulations
WO2010006072A2 (en) 2008-07-08 2010-01-14 The Regents Of The University Of California Mtor modulators and uses thereof
EP2408771B1 (en) 2009-03-17 2016-11-16 Concert Pharmaceuticals, Inc. Pyrazinoisoquinoline compounds
US20120295346A1 (en) * 2009-07-22 2012-11-22 Tufts University Methods and compositions for modulating membrane potential to influence cell behavior
US20130231312A1 (en) * 2010-11-16 2013-09-05 Shengkan Jin Treatment of type ii diabetes and diabetes-associated diseases with safe chemical mitochondrial uncouplers
CA2822621A1 (en) * 2010-12-22 2012-06-28 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase modulators and uses thereof
US20140294957A1 (en) * 2011-04-18 2014-10-02 Maxdelbruck-Centrum Fur Molekulare Medizin Niclosamide for the treatment of cancer metastasis
GB201106814D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compounds
WO2012150543A1 (en) 2011-05-02 2012-11-08 Universite De Geneve Macrocyclic lactones and use thereof
WO2014023329A1 (en) 2012-08-06 2014-02-13 Life And Brain Gmbh Niclosamide and its derivatives for use in the treatment of solid tumors
MX2015003874A (en) 2012-09-26 2015-12-16 Univ California Modulation of ire1.
WO2014062811A2 (en) * 2012-10-16 2014-04-24 New York University METHOD OF TREATING CANCER WITH MODULATORS OF SCFSkp2
CN103356687B (en) * 2012-10-19 2016-06-01 厦门大学 One use of ivermectin and derivatives
EP2931282B1 (en) 2012-12-13 2018-10-31 Novartis AG Pyrimido [4,5-b]quinoline-4,5 (3h,10h)-diones as nonsense mutation suppressors
CN103054846B (en) * 2012-12-18 2015-06-17 杭州雷索药业有限公司 Anti-angiogenic compound and usage thereof
WO2014113467A1 (en) * 2013-01-15 2014-07-24 Board Of Regents, The University Of Texas System Stat3 inhibitor
MX2015013348A (en) 2013-03-20 2016-01-20 Bayer Pharma AG 3-acetylamino-1-(phenyl-heteroaryl-aminocarbonyl or phenyl-heteroaryl-carbonylamino)benzene derivatives for the treatment of hyperproliferative disorders.
EP2976343A2 (en) 2013-03-20 2016-01-27 Bayer Pharma Aktiengesellschaft Substituted n-biphenyl-3-acetylamino-benzamides and n-[3-(acetylamino)phenyl]-biphenyl-carboxamides and their use as inhibitors of the wnt signalling pathway
EP3052655B1 (en) * 2013-09-30 2018-11-07 Institute For Cancer Research D/b/a The Research Institute of Fox Chase Cancer Center Closantel in combination with temozolomide for use in the treatment of a cancer in which is thymine dna glycosylase expressed
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015143012A1 (en) 2014-03-19 2015-09-24 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
CN106459043B (en) 2014-06-03 2018-12-28 诺华股份有限公司 Naphthyridines derovatives
JP2017516828A (en) 2014-06-03 2017-06-22 ノバルティス アーゲー Pyrimido [4,5-b] quinoline -4,5 (3H, 10H) - dione derivatives
US9884862B2 (en) 2014-06-03 2018-02-06 Novartis Ag Pyridopyrimidinedione derivatives
JP2017529393A (en) 2014-09-12 2017-10-05 アンティバイオティクス エーピーエスAntibiotx Aps Antibacterial use of halogenated salicylanilide
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
JP2016088919A (en) * 2014-11-11 2016-05-23 国立研究開発法人産業技術総合研究所 Anticancer agent comprising ivermectin or milbemycin d as active ingredient
CA2976971A1 (en) 2015-02-20 2016-08-25 Bayer Pharma Aktiengesellschaft 3-carbamoylphenyl-4-carboxamide and isophtalamide derivatives as inhibitors of the wnt signalling pathway
JP2018505906A (en) 2015-02-20 2018-03-01 バイエル・ファルマ・アクティエンゲゼルシャフト As inhibitors of Wnt signaling pathway 1,3,4-thiadiazol-2-yl - benzamide derivative
WO2016131810A1 (en) 2015-02-20 2016-08-25 Bayer Pharma Aktiengesellschaft N-phenyl-(morpholin-4-yl or piperazinyl)acetamide derivatives and their use as inhibitors of the wnt signalling pathways
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
EP3349742A1 (en) * 2015-09-16 2018-07-25 Agency For Science, Technology And Research Use of niclosamide in the treatment of p53-deficient cells
CN105687171A (en) * 2016-01-28 2016-06-22 昆明医科大学 New application of aminoquinol
KR20180081938A (en) * 2017-01-09 2018-07-18 연세대학교 산학협력단 Pharmaceutical Composition for Treating or Preventing Cancer Concering Ras Oncogene Target Treatment Containing Niclosamide
EP3403652A1 (en) 2017-05-18 2018-11-21 Veterinärmedizinische Universität Wien Prevention and treatment of fibroblast growth factor 23 (fgf23)-associated disorders including chronic kidney disease (ckd)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4008274A (en) * 1973-06-25 1977-02-15 Yoshitomi Pharmaceutical Industries, Ltd. Certain salicylanilides
US5980948A (en) * 1996-08-16 1999-11-09 Osteotech, Inc. Polyetherester copolymers as drug delivery matrices

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4008274A (en) * 1973-06-25 1977-02-15 Yoshitomi Pharmaceutical Industries, Ltd. Certain salicylanilides
US5980948A (en) * 1996-08-16 1999-11-09 Osteotech, Inc. Polyetherester copolymers as drug delivery matrices

Cited By (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9512125B2 (en) 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
US9527816B2 (en) 2005-05-10 2016-12-27 Intermune, Inc. Method of modulating stress-activated protein kinase system
US9493467B2 (en) 2006-04-04 2016-11-15 The Regents Of The University Of California PI3 kinase antagonists
US8642604B2 (en) 2006-04-04 2014-02-04 The Regents Of The University Of California Substituted pyrazolo[3,2-d]pyrimidines as anti-cancer agents
US9359349B2 (en) 2007-10-04 2016-06-07 Intellikine Llc Substituted quinazolines as kinase inhibitors
US9216982B2 (en) 2008-01-04 2015-12-22 Intellikine Llc Certain chemical entities, compositions and methods
US8703777B2 (en) 2008-01-04 2014-04-22 Intellikine Llc Certain chemical entities, compositions and methods
US8785456B2 (en) 2008-01-04 2014-07-22 Intellikine Llc Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
US8637542B2 (en) 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
US9290450B2 (en) 2008-06-03 2016-03-22 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US8969347B2 (en) 2008-06-03 2015-03-03 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US9096611B2 (en) 2008-07-08 2015-08-04 Intellikine Llc Kinase inhibitors and methods of use
US9296742B2 (en) 2008-09-26 2016-03-29 Intellikine Llc Heterocyclic kinase inhibitors
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
US8697709B2 (en) 2008-10-16 2014-04-15 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
US8785454B2 (en) 2009-05-07 2014-07-22 Intellikine Llc Heterocyclic compounds and uses thereof
US9315505B2 (en) 2009-05-07 2016-04-19 Intellikine Llc Heterocyclic compounds and uses thereof
US9206182B2 (en) 2009-07-15 2015-12-08 Intellikine Llc Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof
US8569323B2 (en) 2009-07-15 2013-10-29 Intellikine, Llc Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof
US9522146B2 (en) 2009-07-15 2016-12-20 Intellikine Llc Substituted Isoquinolin-1(2H)-one compounds, compositions, and methods thereof
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
US9181221B2 (en) 2010-05-21 2015-11-10 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
US8604032B2 (en) 2010-05-21 2013-12-10 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
US9388183B2 (en) 2010-11-10 2016-07-12 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8901133B2 (en) 2010-11-10 2014-12-02 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9290497B2 (en) 2011-01-10 2016-03-22 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US8809349B2 (en) 2011-01-10 2014-08-19 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
US9056877B2 (en) 2011-07-19 2015-06-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8969363B2 (en) 2011-07-19 2015-03-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9115141B2 (en) 2011-08-29 2015-08-25 Infinity Pharmaceuticals, Inc. Substituted isoquinolinones and methods of treatment thereof
US9546180B2 (en) 2011-08-29 2017-01-17 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8785470B2 (en) 2011-08-29 2014-07-22 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9321772B2 (en) 2011-09-02 2016-04-26 The Regents Of The University Of California Substituted pyrazolo[3,4-D]pyrimidines and uses thereof
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9255108B2 (en) 2012-04-10 2016-02-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US9527847B2 (en) 2012-06-25 2016-12-27 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US9359379B2 (en) 2012-10-02 2016-06-07 Intermune, Inc. Anti-fibrotic pyridinones
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9359365B2 (en) 2013-10-04 2016-06-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof

Also Published As

Publication number Publication date
AU2003249244A1 (en) 2004-02-02
WO2004006906A2 (en) 2004-01-22

Similar Documents

Publication Publication Date Title
WO2004019863A3 (en) Combination therapy for treatment of fibrotic disorders
WO2004006906A3 (en) Methods for the treatment of neoplasms
WO2002053187A3 (en) Methods and transdermal compositions for pain relief
WO2004110368A3 (en) Combination therapy for the treatment of hypertension
WO2005027842A3 (en) Combinations of drugs for the treatment of neoplasms
WO2005000217A3 (en) Combination therapy for the treatment of dyslipidemia
WO2000040235A3 (en) Treatment of asthma with mek inhibitors
WO2004016225A8 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2005027993A3 (en) Vascular access preservation in hemodialysis patients
WO2004043341A3 (en) Treatment for hemorrhagic shock
CA2570474A1 (en) A combination composition comprising paracetamol and ibuprofen
WO2003103585A3 (en) Methods of treating angiogenesis, tumor growth, and metastasis
WO2006113802A3 (en) Device for administering electrode stimulation of back and abdominal muscles
WO2004103297A3 (en) Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis
WO2005107726A3 (en) Method for the treatment of back pain
TWI343917B (en) Therapeutic agents useful for treating pain
TWI354561B (en) Pharmaceutical compositions and uses for treatment
CA2480038A1 (en) Substituted 4-aminocyclohexanols
WO2003088923A3 (en) Methods of treating ileus
WO2005082054A3 (en) Combinations for the treatment of fungal infections
CA2495455A1 (en) Use of i.kappa.b-kinase inhibitors in pain therapy
AU2002352501B2 (en) Methods for the treatment of peripheral neural and vascular ailments
TW591026B (en) Inhibitors of alpha4beta1 mediated cell adhesion
WO2004030615A8 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004037205A8 (en) LOW DOSE METHODS FOR TREATING DISORDERS IN WHICH TNFα ACTIVITY IS DETRIMENTAL

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP